• In August 2026, Halozyme Therapeutics reported past second-quarter 2026 results showing revenue of US$481.00 million and net income of US$229.91 million, alongside higher earnings per share and the completion of share repurchases totaling 13,452,356 shares for US$750.00 million across two programs.
• The company also raised its 2026 total revenue guidance to a range of US$1.84 billion to US$1.91 billion, indicating management’s increased confidence after strong first-half performance and capital returns via buybacks.
• We’ll now examine how Halozyme’s raised full-year revenue guidance may influence its existing investment narrative built around ENHANZE-driven royalty growth.

Find 53 companies with promising cash flow potential yet trading below their fair value.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe ENHANZE royalties and partnered biologics can keep driving cash generation despite concentration, patent and pricing risks. The stronger second quarter and higher 2026 revenue guidance reinforce the near term catalyst around ENHANZE adoption, but they do not remove the key risk that a handful of large partners, legal outcomes and reimbursement decisions still heavily influence the story.

The most relevant recent announcement here is the completion of US$750.00 million in buybacks across two programs, retiring 13,452,356 shares, or about 10.91% of the share base. Combined with higher guidance, this puts more focus on how durable Halozyme’s ENHANZE royalty streams are, since future returns increasingly depend on continued partner success to support both earnings and ongoing capital returns.

Yet investors also need to weigh the unresolved patent challenges that could affect ENHANZE royalty protection and are important for shareholders to understand in more detail...

Halozyme Therapeutics' narrative projects $2.1 billion revenue and $1.1 billion earnings by 2029. This requires 12.2% yearly revenue growth and an earnings increase of about $751 million from $348.8 million today.

Uncover how Halozyme Therapeutics' forecasts yield a $86.89 fair value, a 16% downside to its current price.

Exploring Other Perspectives

Before this earnings beat, the most bullish analysts were already modeling revenue near US$2.3 billion and earnings around US$1.2 billion by 2029, a far more optimistic view than the baseline narrative and one that could be tested if ongoing patent challenges unfold differently than expected.

Explore 5 other fair value estimates on Halozyme Therapeutics - why the stock might be worth 16% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.